Reuters reports the agency submitted the proposal for review on October 15, a step that could affect compounded peptides such as BPC-157.
Recap by typeshit. Full story at Reuters on MSN.
Alicia Butterfield claims Anthem denied her Zepbound once the drug got her below morbid obesity. A Los Angeles judge stayed her case pending arbitration.
STAT
Members of Congress from both parties want the FDA to stop imports of copycat versions of Eli Lilly's experimental obesity drug, which is still in trials.
Bloomberg says the boom in GLP-1 use has opened a risky trade in weight loss drugs brought into Brazil illegally.
The pharmacy boards group, per InsideHealthPolicy, ties reported deaths linked to retatrutide to weak enforcement against gray-market peptide sellers.
The GLP-1/GIP drug hit up to 19% mean weight loss over 48 weeks in a Chinese phase 3, with fewer GI side effects, Regeneron says. US trials are still ahead.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
Loading…